Loading...
XNAS
GYRE
Market cap724mUSD
Dec 05, Last price  
7.98USD
1D
1.01%
1Q
3.77%
IPO
18.57%
Name

Catalyst Biosciences Inc

Chart & Performance

D1W1MN
XNAS:GYRE chart
P/E
59.99
P/S
6.85
EPS
0.13
Div Yield, %
—
Shrs. gr., 5y
53.50%
Rev. gr., 5y
616.69%
Revenues
106m
-6.78%
1,179,91727,537,56411,575,93120,085,00025,062,00085,713,00097,637,00057,860,0003,629,000275,0001,750,000399,0001,018,0006,000020,948,0007,338,000794,000113,450,000105,757,000
Net income
12m
P
-28,991,5232,096,529-28,072,887-25,661,000-39,404,00010,899,000-8,529,000-6,998,000-46,705,000-32,623,000-14,762,000-16,945,000-21,561,000-30,055,000-52,887,000-55,542,000-87,933,0002,302,000-92,933,00012,085,000
CFO
-4m
L
-26,246,516-9,892,27724,838,076-28,261,000-24,271,000138,298,000-83,718,000-64,239,000-40,612,000-34,483,000-19,118,000-18,472,000-19,940,000-28,553,000-43,613,000-55,048,000-83,755,000-33,096,00025,892,000-3,641,000
Dividend
Jan 13, 20230.24 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
URL
https://www.catalystbiosciences.com/
IPO date
Apr 12, 2006
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT